

Nutrition

The Future of Healthcare

DIL LIMITED 67th Annual Report, 2018-19

"The doctor of the future will give no medication, but will interest his patients in the care of the human frame, diet and in the cause and prevention of disease."

- Thomas Edison

About this report

This is the annual report of DIL Limited ('DIL'/the 'Company') for the financial year 2018-19 (FY2018-19). A substantial portion of the Company's consolidated revenues and profits are derived from its subsidiary Fermenta Biotech Ltd. (Fermenta). Even though the annual report is that of DIL, it has focused on the performance and prospects of Fermenta for enhanced transparency and better understanding.

Contents

About DIL Limited	6
5 things to know about Fermenta Biotech Limited	8
The Company's senior management.....	10
Fermenta's journey	13
This is how we have grown in the last few years	14
Chairman's review	16
Management's review.....	18
Our business model.....	24
Our business	39
Our business enabler.....	44
Management discussion & analysis.....	47
Boards report.....	56
Standalone financial statement	87
Consolidated financial statement	139
Notice	i

Dietary supplements.
They provide nutrients
extracted from natural
or synthetic sources to
boost immunity.

A preventive step against ailments is now
being preferred over a reactive approach

Micronutrient-fortified foods can address
specific health challenges.

There is a greater focus now on building
immunity than ever.

Dietary supplements work on root causes, not
just symptoms.

There is a greater recognition that we are what
we eat.

Taste can transform the customer's dietary
preference.

Fortified foods have negligible harmful side-
effects.

Vitamin D. The sunshine vitamin.

The one dietary supplement being increasingly recommended is Vitamin D.

This vitamin was first identified as a vitamin early in the 20th century as one that can protect humans from a variety of health issues.

Positioning it as essential for preventive healthcare and overall well-being.





Fermenta and Vitamin D.

Fermenta is one of a handful of global Vitamin D manufacturers.

- Engaged in working with a high sense of customer proximity.
- Focused on developing new downstream applications.
- Enhancing capacities to address growing consumer demand.
- Improving quality (process and product) around global benchmarks.
- Strengthening manufacturing practices (skills, certifications and safety).
- Positioned in the business of tomorrow.





About DIL Limited.

Established in 1951, DIL Limited (earlier known as Duphar-Interfran Limited) is a publicly-listed company that has developed a unique standing in the businesses of pharmaceuticals, biotechnology, environmental solutions and other segments.

DIL Limited holds a 91.20% equity stake in Fermenta Biotech Limited, incorporated in 1986.

A merger is underway with the objective to strengthen economies-of-scale, efficiency and value-accretion.

By pooling skills, talent and experience, the Company has increased its competitiveness, lowered its expenses, simplified its shareholding structure and reduced its borrowing costs.

DIL's portfolio comprises Vitamin D3, niche Active Pharmaceutical Ingredients (APIs), enzymes and other integrated biotechnology products.



The background of the slide is a blurred photograph of a surgeon in an operating room. The surgeon is wearing a blue surgical cap, black-rimmed glasses, and a white surgical mask. They are wearing a white surgical gown and have a small, square, white adhesive device on their right forearm. The lighting is bright and clinical, with some lens flare visible in the upper right corner.

5

things to know
about Fermenta
Biotech Limited